ERBB2 and breast carcinoma: However, when the Akt inhibitor capivasertib was added to fulvestrant, it extended survival of patients with aromatase inhibitor-resistant ER-positive, HER2-negative, advanced breast cancer and with PI3K/Akt/PTEN-altered tumors [380].